News and Trends 14 Aug 2024
CAR-T drugs and parkinsonism: a cause for concern?
CAR-T therapies come with boxed warnings of serious neurotoxic side effects. Now, growing concerns over parkinsonism have led to a clinical trial halt.
- Latest Posts
News and Trends 13 Aug 2024
Biologics vs. drugs: What does Ipsen’s lost case against the FDA mean for the industry?
Ipsen has lost a court case against U.S. regulators to have its blockbuster cancer medication Somatuline Depot regarded as a biologic instead of a drug.
In Depth 9 Aug 2024
The therapeutic potential of circular RNA: Could it soon trump mRNA technology?
Find out about circular RNA, an emerging technology that could hold a lot of promise for next-generation vaccines and gene therapies.
Podcast 9 Aug 2024
Rebroadcast: Epigenetic editing – the power of CRISPR without cutting DNA
This week, we discuss epigenetic editing, why it’s reversible, treating FSHD and other conditions, with Epic Bio founder, Dr Stanley Qi.
Best in Biotech 7 Aug 2024
Top biotech books of all time
Here are 51 great biotech books for this summer 2024 that are bound to get you hooked. From sci-fi to the nitty-gritties of biotech, we’ve got you covered!
In Depth 6 Aug 2024
The biggest private biotech investments in July 2024
The companies Cardurion Pharmaceuticals, Beacon Therapeutics, and Third Arc Bio bagged the biggest private biotech investments in July 2024.
ADVERTISEMENT
ADVERTISEMENT
Best in Biotech 2 Aug 2024
Six epigenetics companies making strides in 2024
In this article, we take a look at six epigenetics companies that are significant as well as up-and-coming players in the industry.
Podcast 2 Aug 2024
Rebroadcast: How does AI assist drug discovery?
Listen to our podcast to discover how AI is revolutionizing drug discovery by tackling “undruggable” targets like KRAS.
News and Trends 1 Aug 2024
European regulators reject Alzheimer’s drug Leqembi: is it downhill from here?
European regulators have now refused to market the Alzheimer’s drug Leqembi after it was approved by the FDA last year.
In Depth 1 Aug 2024
CureVac: From a failed drug to a €1.45 billion deal
In 2021, CureVac’s COVID-19 candidate came short. Discover how the company leveraged its deal with GSK to restructure and turn things around.
In Depth 30 Jul 2024
Why is the immunology and inflammation market suddenly attracting a wave of investment?
Discover why the immunology and inflammation market has recently been attracting a major wave of investment.
News and Trends 29 Jul 2024
Influenza solution deals pile up as pandemic preparedness increases
Influenza deals have been piling up in the last few weeks. Discover why that is and how are companies and government preparing for pandemics.
ADVERTISEMENT
